Severe cholestasis related to intraconazole for the treatment of onychomycosis

Am J Gastroenterol. 1999 Dec;94(12):3632-3. doi: 10.1111/j.1572-0241.1999.01623.x.

Abstract

We describe a case of prolonged cholestasis temporally associated with the use of itraconazole for onychomycosis. Peak bilirubin level of 32.0 mg/dl was documented approximately 2 months after discontinuation of the patient's itraconazole therapy, with symptoms of cholestasis persisting more than 1 month after the peak in bilirubin. Physicians should be aware of the potential for severe cholestasis associated with itraconazole usage.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antifungal Agents / administration & dosage
  • Antifungal Agents / adverse effects*
  • Bilirubin / blood
  • Cholestasis, Intrahepatic / chemically induced*
  • Humans
  • Itraconazole / administration & dosage
  • Itraconazole / adverse effects*
  • Liver Function Tests
  • Male
  • Onychomycosis / drug therapy*

Substances

  • Antifungal Agents
  • Itraconazole
  • Bilirubin